# PAION

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/paion

- Industry: Biotechnology
- Headquarters: Aachen, Germany
- Website: www.paion.com
- Total disclosed funding: $12M
- Latest round: Series D (May 29, 2004)
- Investors on record: 6

## About

PAION AG i.L. specializes in developing and marketing innovative pharmaceutical products, particularly in anesthesia and sedation therapies for surgical and procedural applications.Founded in 2000, PAION AG i.L. is headquartered in Aachen, Germany, and focuses on the research, development, and commercialization of anesthetic medications. The company has pivoted towards expanding its product line within the anesthesia domain. Tilmann Bur serves as the CEO. In February 2005, PAION raised EUR 40 million in its IPO at EUR 8 each, marking a significant milestone in its funding history. The company has secured a total of USD 4.10 mn through various funding rounds, with the latest round occurring in 2005.PAION AG i.L. specializes in pharmaceutical products, focusing primarily on anesthesia and sedation therapies. The company's flagship product offerings include innovative anesthetic agents designed to enhance patient safety and comfort during medical procedures, addressing the needs of healthcare providers and patients undergoing surgery. PAION's products are marketed primarily in Europe and select international markets, serving hospitals, outpatient surgical centers, and healthcare institutions seeking effective anesthetic solutions. The company aims to improve procedural outcomes through its advanced therapeutic agents, which are supported by rigorous clinical research and development.In the most recent fiscal year, 2022, PAION AG i.L. reported a revenue of USD 35.04 mn and an EBITDA of USD 3.39 mn. The company operates by selling its anesthetic products directly to healthcare institutions and through partnerships with pharmaceutical distributors. Sales are primarily conducted under bulk purchasing agreements or direct procurement contracts, emphasizing its commitment to meeting the demands of safe anesthesia practices in medical environments.PAION plans to leverage its recent funding to further enhance its product offerings in the anesthesia sector. The funds from the IPO will support the development of upcoming anesthetic products, with a focus on expanding into new geographic markets. PAION aims to penetrate additional regions across Europe and beyond, reinforcing its market presence. The company is actively working to finalize new product releases that align with its growth objectives, signaling a strategic focus on innovating within its core therapeutic area.

## Funding rounds

- Series D, May 29, 2004, $12M — NeoMed, IPSA, The 3i Group - LISTED FUND, APICAP, Credit Suisse Entrepreneur Capital, Reference Cap AG

## Investors

- NeoMed (https://capitalatlas.ai/funds/neomed) — Series D
- IPSA (https://capitalatlas.ai/funds/ipsa) — Series D
- The 3i Group - LISTED FUND — Series D
- APICAP (https://capitalatlas.ai/funds/apicap) — Series D
- Credit Suisse Entrepreneur Capital (https://capitalatlas.ai/funds/credit-suisse-entrepreneur-capital) — Series D
- Reference Cap AG — Series D